Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOPIC: Topical imiquimod for high-grade cervical intraepithelial neoplasia
2013-001260-34Phase 4Terminated
- Sponsor
- Maastricht University Medical Center+
- Start
- Jun 2014
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of imiquimod in cervical intraepithelial neoplasia (CIN) (2 arms), sponsored by Maastricht University Medical Center+. Primary endpoint: Regression of CIN2-3 lesions at 20 weeks. Started Jun 2014; status: terminated.
02
Drugs
imiquimod
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on 2013-001260-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001260-34.